{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:16:13Z","timestamp":1787026573192,"version":"build-2736575974"},"reference-count":183,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Although the response rates to chimeric antigen receptor T (CAR-T) therapy in patients with treatment-resistant lymphoma are high, the majority of patients relapse. CAR-T cell exhaustion, characterized by the progressive loss of T-cell effector functions due to several molecular and epigenetic pathways, is a major mediator of CAR-T cell failure. Strategies to prevent CAR-T cell exhaustion, including modifications to the CAR structure, addition of adjunctive agents, and alternative product manufacturing strategies have shown promise. In this review, we discuss the mechanisms of CAR-T cell exhaustion and describe strategies for its mitigation, with the aim of supporting further research in this critical area.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1727926","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T05:37:37Z","timestamp":1776749857000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting CAR-T cell exhaustion in non-Hodgkin lymphoma: mechanistic insights and emerging clinical strategies"],"prefix":"10.3389","volume":"17","author":[{"given":"Anirudh","family":"Rao","sequence":"first","affiliation":[{"name":"Department of Medicine, Temple University Hospital","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Darwish","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Fox Chase Cancer Center","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry S.","family":"Campbell","sequence":"additional","affiliation":[{"name":"Institute for Cancer Research, Fox Chase Cancer Center","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Khanal","sequence":"additional","affiliation":[{"name":"Department of Bone Marrow Transplant & Cellular Therapies, Fox Chase Cancer Center","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Fung","sequence":"additional","affiliation":[{"name":"Department of Bone Marrow Transplant & Cellular Therapies, Fox Chase Cancer Center","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Stack","sequence":"additional","affiliation":[{"name":"Department of Bone Marrow Transplant & Cellular Therapies, Fox Chase Cancer Center","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.46989\/001c.124277","article-title":"Overview of approved CAR-T products and utility in clinical practice","volume":"6","author":"Bhaskar","year":"2024","journal-title":"Clin Hematol Int"},{"key":"B2","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291x(87)90502-x","article-title":"Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions","volume":"149","author":"Kuwana","year":"1987","journal-title":"Biochem Biophys Res Commun"},{"key":"B4","doi-asserted-by":"publisher","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/biom12091303","article-title":"Co-stimulatory receptor signaling in CAR-T cells","volume":"12","author":"Honikel","year":"2022","journal-title":"Biomolecules"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403302","article-title":"Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia","volume":"18","author":"Imai","year":"2004","journal-title":"Leukemia"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1172\/JCI46110","article-title":"CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients","volume":"121","author":"Savoldo","year":"2011","journal-title":"J Clin Invest"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021567","article-title":"Durable response after tisagenlecleucel in adults with relapsed\/refractory follicular lymphoma: ELARA trial update","volume":"143","author":"Dreyling","year":"2024","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018893","article-title":"5-year follow-up supports curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1)","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020854","article-title":"Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001","volume":"143","author":"Abramson","year":"2024","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","first-page":"7013","DOI":"10.1200\/JCO.2024.42.16_suppl.7013","article-title":"Lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pt) with R\/R large B-cell lymphoma (LBCL): 3-year follow-up (FU","volume":"42","author":"Kamdar","year":"2024","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02986-9","article-title":"Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study","volume":"30","author":"Morschhauser","year":"2024","journal-title":"Nat Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02214","article-title":"Lisocabtagene maraleucel in relapsed\/refractory mantle cell lymphoma: primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a phase I multicenter seamless design study","volume":"42","author":"Wang","year":"2024","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01052-8","article-title":"Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1\u20132 study","volume":"402","author":"Siddiqi","year":"2023","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)02435-3","article-title":"Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study","volume":"407","author":"Palomba","year":"2026","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02370","article-title":"Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016945","article-title":"Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis","volume":"140","author":"Di Blasi","year":"2022","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01739-2","article-title":"Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma","volume":"37","author":"Alarcon Tomas","year":"2023","journal-title":"Leukemia"},{"key":"B26","doi-asserted-by":"publisher","first-page":"7921","DOI":"10.1038\/s41467-024-51978-3","article-title":"IL-4 drives exhaustion of CD8+ CART cells","volume":"15","author":"Stewart","year":"2024","journal-title":"Nat Commun"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25505","article-title":"Outcomes of patients with large B\u2010cell lymphomas and progressive disease following CD19\u2010specific CAR T\u2010cell therapy","volume":"94","author":"Chow","year":"2019","journal-title":"Am J Hematol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ccell.2022.12.005","article-title":"Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas","volume":"41","author":"Sworder","year":"2023","journal-title":"Cancer Cell"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0184-6","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02664","article-title":"Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies","volume":"10","author":"Xu","year":"2019","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1146\/annurev-immunol-090222-110914","article-title":"T cell exhaustion","volume":"42","author":"Baessler","year":"2024","journal-title":"Annu Rev Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2010.00926.x","article-title":"Generation of effector CD8+ T cells and their conversion to memory T cells","volume":"236","author":"Cui","year":"2010","journal-title":"Immunol Rev"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/362758a0","article-title":"Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells","volume":"362","author":"Moskophidis","year":"1993","journal-title":"Nature"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1084\/jem.188.12.2205","article-title":"Viral immune evasion due to persistence of activated T cells without effector function","volume":"188","author":"Zajac","year":"1998","journal-title":"J Exp Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.04.004","article-title":"Decoding and overcoming T cell exhaustion: Epigenetic and transcriptional dynamics in CAR-T cells against solid tumors","volume":"32","author":"Ahn","year":"2024","journal-title":"Mol Ther"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2010.03255.x","article-title":"T-cell exhaustion: characteristics, causes and conversion","volume":"129","author":"Yi","year":"2010","journal-title":"Immunology"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-00834-9","article-title":"Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion","volume":"22","author":"Scharping","year":"2021","journal-title":"Nat Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202002566R","article-title":"Role of TCF\u20101 in differentiation, exhaustion, and memory of CD8 + T cells: a review","volume":"35","author":"Zhang","year":"2021","journal-title":"FASEB J"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.162","article-title":"T-cell exhaustion in the tumor microenvironment","volume":"6","author":"Jiang","year":"2015","journal-title":"Cell Death Dis"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-023-04737-8","article-title":"Cancer immune escape: the role of antigen presentation machinery","volume":"149","author":"Kallingal","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41392-024-01868-3","article-title":"Targeting cytokine and chemokine signaling pathways for cancer therapy","volume":"9","author":"Yi","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/cells12212532","article-title":"Role of cytokines and other soluble factors in tumor development: rationale for new therapeutic strategies","volume":"12","author":"Cavazzoni","year":"2023","journal-title":"Cells"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1177\/20503121211069012","article-title":"Tumor promoting roles of IL-10, TGF-\u03b2, IL-4, and IL-35: its implications in cancer immunotherapy","volume":"10","author":"Mirlekar","year":"2022","journal-title":"SAGE Open Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1080\/08830185.2024.2401352","article-title":"The molecular landscape of T cell exhaustion in the tumor microenvironment and reinvigoration strategies","volume":"43","author":"Heidari-Foroozan","year":"2024","journal-title":"Int Rev Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1016\/j.immuni.2022.10.002","article-title":"Tumor-associated macrophages expressing the transcription factor IRF8 promote T cell exhaustion in cancer","volume":"55","author":"Nixon","year":"2022","journal-title":"Immunity"},{"key":"B47","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.ccell.2022.05.004","article-title":"Spatiotemporal co-dependency between macrophages and exhausted CD8+ T cells in cancer","volume":"40","author":"Kersten","year":"2022","journal-title":"Cancer Cell"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01906","article-title":"Hypoxia induces mitochondrial defect that promotes T cell exhaustion in tumor microenvironment through MYC-regulated pathways","volume":"11","author":"Liu","year":"2020","journal-title":"Front Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102931","article-title":"CAR-T design: elements and their synergistic function","volume":"58","author":"Jayaraman","year":"2020","journal-title":"EBioMedicine"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.abe2606","article-title":"Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function","volume":"14","author":"Salter","year":"2021","journal-title":"Sci Signal"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01676-0","article-title":"Single-cell ATAC-seq maps the comprehensive and dynamic chromatin accessibility landscape of CAR-T cell dysfunction","volume":"36","author":"Jiang","year":"2022","journal-title":"Leukemia"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0781-7","article-title":"Strength of tonic T cell receptor signaling instructs T follicular helper cell-fate decisions","volume":"21","author":"Bartleson","year":"2020","journal-title":"Nat Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-023-00789-0","article-title":"Tuning charge density of chimeric antigen receptor optimizes tonic signaling and CAR-T cell fitness","volume":"33","author":"Chen","year":"2023","journal-title":"Cell Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-20-0451","article-title":"Modifications to the framework regions eliminate chimeric antigen receptor tonic signaling","volume":"9","author":"Landoni","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3390\/cells11071140","article-title":"Molecular and functional signatures associated with CAR T cell exhaustion and impaired clinical response in patients with B cell Malignancies","volume":"11","author":"Beider","year":"2022","journal-title":"Cells"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00689-z","article-title":"Clinical implications of T cell exhaustion for cancer immunotherapy","volume":"19","author":"Chow","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00530-z","article-title":"A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains","volume":"18","author":"Cappell","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-0096","article-title":"CD28 costimulation augments CAR signaling in NK cells via the LCK\/CD3\u03b6\/ZAP70 signaling axis","volume":"14","author":"Acharya","year":"2024","journal-title":"Cancer Discov"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0186","article-title":"Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells","volume":"3","author":"Frigault","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B60","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ccell.2019.12.014","article-title":"THEMIS-SHP1 recruitment by 4-1BB tunes LCK-mediated priming of chimeric antigen receptor-redirected T cells","volume":"37","author":"Sun","year":"2020","journal-title":"Cancer Cell"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aay8248","article-title":"4-1BB costimulation promotes CAR T cell survival through noncanonical NF-\u03baB signaling","volume":"13","author":"Philipson","year":"2020","journal-title":"Sci Signal"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15102767","article-title":"Difference in efficacy and safety of anti-CD19 chimeric antigen receptor T-cell therapy containing 4-1BB and CD28 co-stimulatory domains for B-cell acute lymphoblastic leukemia","volume":"15","author":"Wu","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B63","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13045-021-01144-9","article-title":"Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma","volume":"14","author":"Maloney","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2113526","article-title":"Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphoma","volume":"63","author":"Oluwole","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"B65","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1182\/blood-2024-200937","article-title":"Matching-adjusted indirect comparison (MAIC) of lisocabtagene maraleucel (liso-cel) versus axicabtagene ciloleucel (axi-cel) for second-line (2L) treatment of patients (pts) with refractory\/early relapsed (R\/R) large B-cell lymphoma (LBCL): Update with 34","volume":"144","author":"Abramson","year":"2024","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.e19049","article-title":"Matching-adjusted indirect comparison (MAIC) of lisocabtagene maraleucel (liso-cel) versus axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) for treatment of third-line or later (3L+) R\/R follicular lymphoma (FL): Update with 24 months of","volume":"43","author":"Boardman","year":"2025","journal-title":"J Clin Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.698607","article-title":"Efficacy and safety of CAR-T cell products axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel for the treatment of hematologic Malignancies: A systematic review and meta-analysis","volume":"11","author":"Meng","year":"2021","journal-title":"Front Oncol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1182\/blood-2023-179509","article-title":"Chimeric antigen receptor T-cell therapy in elderly patients with relapsed or refractory large B-cell lymphoma: A multicenter study","volume":"142","author":"Tun","year":"2023","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.287010","article-title":"Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: An inverse probability of treatment weighting analysis with 3-year follow up","volume":"9","author":"Portuguese","year":"2025","journal-title":"Haematologica"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024012992","article-title":"A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma","volume":"9","author":"Looka","year":"2025","journal-title":"Blood Adv"},{"key":"B71","first-page":"4493","article-title":"Real World Comparison of Axicabtagene Ciloleucel and Lisocabtagene Maraleucel in Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume-title":"Blood","author":"Yu","year":"2024"},{"key":"B72","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1182\/blood-2024-200269","article-title":"Real world comparison of efficacy and safety of fludarabine-versus bendamustine-based lymphodepleting chemotherapy for cd19 chimeric antigen receptor (car) t-cell therapy in relapse\/refractory (r\/r) large b-cell lymphoma (LBCL)","volume":"144","author":"Ali","year":"2024","journal-title":"Blood"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1905675116","article-title":"TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion","volume":"116","author":"Seo","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.ccell.2022.09.013","article-title":"Depletion of BATF in CAR-T cells enhances antitumor activity by inducing resistance against exhaustion and formation of central memory cells","volume":"40","author":"Zhang","year":"2022","journal-title":"Cancer Cell"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1152498","article-title":"Monitoring of kinetics and exhaustion markers of circulating CAR-T cells as early predictive factors in patients with B-cell Malignancies","volume":"14","author":"Garc\u00eda-Calder\u00f3n","year":"2023","journal-title":"Front Immunol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.4504","article-title":"Implications of high tumor burden on chimeric antigen receptor T-cell immunotherapy: A review","volume":"10","author":"Ventin","year":"2024","journal-title":"JAMA Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011768","article-title":"Acquisition of an immunosuppressive microenvironment after anti-CD19 CAR T-cell therapy is associated with T-cell dysfunction and resistance","volume":"13","author":"Ponzo","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01916-x","article-title":"Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma","volume":"28","author":"Scholler","year":"2022","journal-title":"Nat Med"},{"key":"B79","doi-asserted-by":"publisher","first-page":"7536","DOI":"10.1200\/JCO.2021.39.15_suppl.7536","article-title":"Favorable tumor immune microenvironment (TME) and robust chimeric antigen receptor (CAR) T-cell expansion may overcome tumor burden (TB) and promote durable efficacy with axicabtagene ciloleucel (axi-cel) in large B-cell lymphoma (LBCL)","volume":"39","author":"Chou","year":"2021","journal-title":"J Clin Oncol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1186383","article-title":"Cell metabolism-based optimization strategy of CAR-T cell function in cancer therapy","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1016\/j.immuni.2025.08.008","article-title":"Oxidative-stress-induced telomere instability drives T cell dysfunction in cancer","volume":"58","author":"Rivadeneira","year":"2025","journal-title":"Immunity"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-024-01999-3","article-title":"Dysfunction of exhausted T cells is enforced by MCT11-mediated lactate metabolism","volume":"25","author":"Peralta","year":"2024","journal-title":"Nat Immunol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"5183","DOI":"10.1038\/s41467-024-49495-4","article-title":"Cholesterol efflux from C1QB-expressing macrophages is associated with resistance to chimeric antigen receptor T cell therapy in primary refractory diffuse large B cell lymphoma","volume":"15","author":"Yan","year":"2024","journal-title":"Nat Commun"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.03.023","article-title":"High-multiplex single-cell imaging analysis reveals tumor immune contexture associated with clinical outcomes after CAR T cell therapy","volume":"32","author":"Jin","year":"2024","journal-title":"Mol Ther"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.ccell.2025.05.013","article-title":"CSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma","volume":"43","author":"Stahl","year":"2025","journal-title":"Cancer Cell"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1000173","article-title":"Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function","volume":"184","author":"Schmid","year":"2010","journal-title":"J Immunol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibtech.2021.12.009","article-title":"Roadmap to affinity-tuned antibodies for enhanced chimeric antigen receptor T cell function and selectivity","volume":"40","author":"Vander Mause","year":"2022","journal-title":"Trends Biotechnol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0549-5","article-title":"Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR","volume":"25","author":"Ghorashian","year":"2019","journal-title":"Nat Med"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2406526","article-title":"Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia","volume":"391","author":"Roddie","year":"2024","journal-title":"N Engl J Med"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009485","article-title":"Preclinical development of three novel CARs targeting CD79b for the treatment of non-Hodgkin\u2019s lymphoma and characterization of the loss of the target antigen","volume":"12","author":"Esquinas","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0290-5","article-title":"Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency","volume":"25","author":"Feucht","year":"2019","journal-title":"Nat Med"},{"key":"B92","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1158\/2326-6066.CIR-20-0253","article-title":"CD28 costimulatory domain-targeted mutations enhance chimeric antigen receptor T-cell function","volume":"9","author":"Boucher","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02424","article-title":"Results from first-in-human phase I study of a novel CD19-1XX chimeric antigen receptor with calibrated signaling in large B-cell lymphoma","volume":"43","author":"Park","year":"2025","journal-title":"J Clin Oncol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2559","article-title":"Combined CD28 and 4-1BB costimulation potentiates affinity-tuned chimeric antigen receptor\u2013engineered T cells","volume":"25","author":"Drent","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003354","article-title":"4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells","volume":"9","author":"Roselli","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02392-7","article-title":"Third-generation anti-CD19 CAR T cells for relapsed\/refractory chronic lymphocytic leukemia: A phase 1\/2 study","volume":"38","author":"Derigs","year":"2024","journal-title":"Leukemia"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.09.009","article-title":"In vivo fate and activity of second- versus third-generation CD19-specific CAR-T cells in B cell non-Hodgkin\u2019s lymphomas","volume":"26","author":"Ramos","year":"2018","journal-title":"Mol Ther"},{"key":"B98","doi-asserted-by":"publisher","first-page":"TPS7580","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS7580","article-title":"CRC-403: A phase 1\/2 study of bbT369, a dual targeting CAR T-cell drug product with a gene edit, in relapsed and\/or refractory B-cell non-Hodgkin lymphoma (NHL)","volume":"40","author":"Locke","year":"2022","journal-title":"J Clin Oncol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1182\/blood-2025-265","article-title":"A phase 1 study of KITE-753 or KITE-363 in patients with relapsed\/refractory B-cell lymphoma: Initial safety and preliminary efficacy of KITE-753 and updated results of KITE-363","volume":"146","author":"Dahiya","year":"2025","journal-title":"Blood"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022293","article-title":"IL-18-secreting multiantigen targeting CAR T cells eliminate antigen-low myeloma in an immunocompetent mouse model","volume":"144","author":"Ng","year":"2024","journal-title":"Blood"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2408771","article-title":"Enhanced CAR T-cell therapy for lymphoma after previous failure","volume":"392","author":"Svoboda","year":"2025","journal-title":"N Engl J Med"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2022.2114254","article-title":"Current updates on generations, approvals, and clinical trials of CAR T-cell therapy","volume":"18","author":"Asmamaw Dejenie","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a JAK\u2013STAT signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat Med"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115691","article-title":"Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma","volume":"168","author":"Yuti","year":"2023","journal-title":"BioMed Pharmacother"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109442","article-title":"Anti-CD19 chimeric antigen receptor T cells secreting anti-PD-L1 single-chain variable fragment attenuate PD-L1 mediated T cell inhibition","volume":"113","author":"Yuti","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"B107","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/s41598-017-00462-8","article-title":"CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells","volume":"7","author":"Rupp","year":"2017","journal-title":"Sci Rep"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133977","article-title":"TGF-\u03b2 inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors","volume":"5","author":"Tang","year":"2020","journal-title":"JCI Insight"},{"key":"B109","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1038\/s41467-024-47799-z","article-title":"CAR affinity modulates the sensitivity of CAR-T cells to PD-1\/PD-L1-mediated inhibition","volume":"15","author":"Andreu-Saumell","year":"2024","journal-title":"Nat Commun"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2281-2","article-title":"CRISPR\/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions","volume":"68","author":"Hu","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"B111","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1016\/j.immuni.2023.09.001","article-title":"Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells","volume":"56","author":"Agarwal","year":"2023","journal-title":"Immunity"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001688","article-title":"Deletion of Cbl-b inhibits CD8+ T-cell exhaustion and promotes CAR T-cell function","volume":"9","author":"Kumar","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B113","doi-asserted-by":"publisher","first-page":"7025","DOI":"10.1200\/JCO.2024.42.16_suppl.7025","article-title":"A CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (CB-010) in patients with relapsed\/refractory B cell non-Hodgkin lymphoma (r\/r B-NHL): Updated phase 1 results from the ANTLER trial","volume":"42","author":"Hu","year":"2024","journal-title":"J Clin Oncol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102010","article-title":"Safety and efficacy of CRISPR-based non-viral PD1 locus specifically integrated anti-CD19 CAR-T cells in patients with relapsed or refractory Non-Hodgkin\u2019s lymphoma: a first-in-human phase I study","volume":"60","author":"Hu","year":"2023","journal-title":"EClinicalMedicine"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101085","article-title":"A novel dominant-negative PD-1 armored anti-CD19 CAR T cell is safe and effective against refractory\/relapsed B cell lymphoma","volume":"14","author":"Liu","year":"2021","journal-title":"Transl Oncol"},{"key":"B116","doi-asserted-by":"crossref","DOI":"10.1038\/s41588-023-01554-0","article-title":"Transcriptional and epigenetic regulators of human CD8+ T cell function identified through orthogonal CRISPR screens","volume-title":"Nat Genet.","author":"McCutcheon","year":"2023"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adk7640","article-title":"Comparative analysis of Bcl-2 family protein overexpression in CAR T cells alone and in combination with BH3 mimetics","volume":"16","author":"Korell","year":"2024","journal-title":"Sci Transl Med"},{"key":"B118","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1182\/blood-2023-189747","article-title":"Bclxl prevents progressive exhaustion in BCMA CAR T cells with maintenance of high TCF1 expressing T cells","volume":"142","author":"Poorebrahim","year":"2023","journal-title":"Blood"},{"key":"B119","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40364-021-00275-y","article-title":"TOX as a potential target for immunotherapy in lymphocytic Malignancies","volume":"9","author":"Liang","year":"2021","journal-title":"biomark Res"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-020-00722-9","article-title":"Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer","volume":"12","author":"Kim","year":"2020","journal-title":"Genome Med"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1324-y","article-title":"TOX is a critical regulator of tumour-specific T cell differentiation","volume":"571","author":"Scott","year":"2019","journal-title":"Nature"},{"key":"B122","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41392-019-0041-1","article-title":"Targeting NR4As, a new strategy to fine-tune CAR-T cells against solid tumors","volume":"4","author":"Li","year":"2019","journal-title":"Signal Transduct Target Ther"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.84","article-title":"TGF-\u03b2 upregulates CD70 expression and induces exhaustion of effector memory T cells in B-cell non-Hodgkin\u2019s lymphoma","volume":"28","author":"Yang","year":"2014","journal-title":"Leukemia"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-023-01123-9","article-title":"Inactivation of TGF-\u03b2 signaling in CAR-T cells","volume":"21","author":"Yang","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"B125","doi-asserted-by":"publisher","first-page":"4198","DOI":"10.1182\/blood-2018-99-119502","article-title":"Sequential anti-CD19 directed chimeric antigen receptor modified T-cell therapy (CART19) and PD-1 blockade with pembrolizumab in patients with relapsed or refractory B-cell non-hodgkin lymphomas","volume":"132","author":"Chong","year":"2018","journal-title":"Blood"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2020-CT055","article-title":"Abstract CT055: Phase 1\/2 primary analysis of ZUMA-6: Axicabtagene ciloleucel (Axi-Cel) in combination With atezolizumab (Atezo) for the treatment of patients (Pts) with refractory diffuse large B cell lymphoma (DLBCL)","volume":"80","author":"Jacobson","year":"2020","journal-title":"Cancer Res"},{"key":"B127","year":""},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007317","article-title":"Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia","volume":"6","author":"Gill","year":"2022","journal-title":"Blood Adv"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007779","article-title":"Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r\/r DLBCL: phase 1b PORTIA study results","volume":"7","author":"Jaeger","year":"2023","journal-title":"Blood Adv"},{"key":"B130","volume-title":"A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed\/Refractory B-cell Malignancies (PLATFORM). Identifier: NCT03330691. Updated 2023 Jul 12. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03330691. No Title","year":""},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021306","article-title":"CAR T cells and time-limited ibrutinib as treatment for relapsed\/refractory mantle cell lymphoma: the phase 2 TARMAC study","volume":"143","author":"Minson","year":"2024","journal-title":"Blood"},{"key":"B132","doi-asserted-by":"publisher","first-page":"6546","DOI":"10.1182\/blood-2024-205304","article-title":"BTK inhibitor synergizes with CD19-targeted chimeric antigen receptor-T cells in patients with relapsed or refractory B-cell lymphoma: an open-label pragmatic clinical trial","volume":"144","author":"Luo","year":"2024","journal-title":"Blood"},{"key":"B133","volume-title":"Cluster of Differentiation Antigen 19\/22 (CD19\/22) CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma (ALEXANDER). Identifier: NCT03287817. Updated 2023 May 9. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03287817","year":""},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-629600","article-title":"Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma","volume":"126","author":"Kiyasu","year":"2015","journal-title":"Blood"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.4161\/onci.26286","article-title":"Blockade of PD-1 immunosuppression boosts CAR T-cell therapy","volume":"2","author":"John","year":"2013","journal-title":"Oncoimmunology"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011287","article-title":"Timing of anti-PD-L1 antibody initiation affects efficacy\/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma","volume":"8","author":"Hirayama","year":"2024","journal-title":"Blood Adv"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012634","article-title":"Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy","volume":"139","author":"Chong","year":"2022","journal-title":"Blood"},{"key":"B138","year":""},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-024-00940-y","article-title":"Efficacy of programmed cell death 1 inhibitor maintenance after chimeric antigen receptor T cells in patients with relapsed\/refractory B-cell non-Hodgkin-lymphoma","volume":"47","author":"Xin","year":"2024","journal-title":"Cell Oncol (Dordrecht Netherlands)"},{"key":"B140","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s13045-022-01353-w","article-title":"BTK inhibitors in the treatment of hematological Malignancies and inflammatory diseases: mechanisms and clinical studies","volume":"15","author":"Alu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000412","article-title":"Bruton tyrosine kinase inhibitors: present and future","volume":"25","author":"Burger","year":"2019","journal-title":"Cancer J"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2023.03.005","article-title":"Bruton tyrosine kinase inhibitors preserve anti-CD19 chimeric antigen receptor T-cell functionality and reprogram tumor micro-environment in B-cell lymphoma","volume":"25","author":"Luo","year":"2023","journal-title":"Cytotherapy"},{"key":"B144","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1182\/blood-2025-1010","article-title":"Phase II, single-arm, open-label, multicenter study: Efficacy of adjunctive Bruton\u2019s tyrosine kinase inhibitor (BTKi) zanubrutinib and chimeric antigen receptor (CART) in aggressive B-cell non-hodgkins lymphoma (aNHL)","volume":"146","author":"Karmali","year":"2025","journal-title":"Blood"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.4.12.1963","article-title":"Thalidomide-derived immunomodulatory drugs as therapeutic agents","volume":"4","author":"Galustian","year":"2004","journal-title":"Expert Opin Biol Ther"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12708","article-title":"Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.)","volume":"164","author":"Gandhi","year":"2014","journal-title":"Br J Haematol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science (80-)"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100695","article-title":"Revving the CAR - Combination strategies to enhance CAR T cell effectiveness","volume":"45","author":"Bansal","year":"2021","journal-title":"Blood Rev"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-02-0361","article-title":"Immunomodulatory drug costimulates T cells via the B7-CD28 pathway","volume":"103","author":"LeBlanc","year":"2004","journal-title":"Blood"},{"key":"B150","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00262-012-1308-3","article-title":"Lenalidomide enhances anti-myeloma cellular immunity","volume":"62","author":"Luptakova","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1172\/JCI35017","article-title":"Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug","volume":"118","author":"Ramsay","year":"2008","journal-title":"J Clin Invest"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24442","article-title":"IL-21 modulates memory and exhaustion phenotype of T-cells in a fatty acid oxidation-dependent manner","volume":"9","author":"Loschinski","year":"2018","journal-title":"Oncotarget"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2043299","article-title":"Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia","volume":"63","author":"Tettamanti","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb6295","article-title":"Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide","volume":"13","author":"Jan","year":"2021","journal-title":"Sci Transl Med"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101804","article-title":"Degradation of IKZF1 prevents epigenetic progression of T cell exhaustion in an antigen-specific assay","volume":"5","author":"Tay","year":"2024","journal-title":"Cell Rep Med"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101584","article-title":"Iberdomide increases innate and adaptive immune cell subsets in the bone marrow of patients with relapsed\/refractory multiple myeloma","volume":"5","author":"Van Oekelen","year":"2024","journal-title":"Cell Rep Med"},{"key":"B157","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1182\/blood-2023-189445","article-title":"Mezigdomide reverses T-cell exhaustion through degradation of Aiolos\/Ikaros and reinvigoration of cytokine production pathways","volume":"142","author":"Chiu","year":"2023","journal-title":"Blood"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.08.003","article-title":"Epigenetic strategies to boost CAR T cell therapy","volume":"29","author":"Akbari","year":"2021","journal-title":"Mol Ther"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf2807","article-title":"Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade","volume":"354","author":"Pauken","year":"2016","journal-title":"Science"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1038\/nature25144","article-title":"Effector CD8 T cells dedifferentiate into long-lived memory cells","volume":"552","author":"Youngblood","year":"2017","journal-title":"Nature"},{"key":"B161","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41467-020-20696-x","article-title":"Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming","volume":"12","author":"Wang","year":"2021","journal-title":"Nat Commun"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01787","article-title":"Decitabine-mediated epigenetic reprograming enhances anti-leukemia efficacy of CD123-targeted chimeric antigen receptor T-cells","volume":"11","author":"You","year":"2020","journal-title":"Front Immunol"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S198567","article-title":"Decitabine enhances cytotoxic effect of T cells with an anti-CD19 chimeric antigen receptor in treatment of lymphoma","volume":"12","author":"Li","year":"2019","journal-title":"Onco Targets Ther"},{"key":"B164","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.ccell.2025.01.013","article-title":"EZH1\/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models","volume":"43","author":"Porazzi","year":"2025","journal-title":"Cancer Cell"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114065","article-title":"Class I HDAC inhibitors enhance antitumor efficacy and persistence of CAR-T cells by activation of the Wnt pathway","volume":"43","author":"Zhu","year":"2024","journal-title":"Cell Rep"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1172\/JCI145459","article-title":"BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia","volume":"131","author":"Kong","year":"2021","journal-title":"J Clin Invest"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.07.021","article-title":"T cell factor 1-expressing memory-like CD8+ T cells sustain the immune response to chronic viral infections","volume":"45","author":"Utzschneider","year":"2016","journal-title":"Immunity"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aai8593","article-title":"The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness","volume":"1","author":"Wu","year":"2016","journal-title":"Sci Immunol"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.07.029","article-title":"The PI3K pathway in human disease","volume":"170","author":"Fruman","year":"2017","journal-title":"Cell"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001795","article-title":"Duvelisib for CLL\/SLL and follicular non-Hodgkin lymphoma","volume":"134","author":"Patel","year":"2019","journal-title":"Blood"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011597","article-title":"PI3K\u03b4\/\u03b3 inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity","volume":"139","author":"Funk","year":"2022","journal-title":"Blood"},{"key":"B172","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13045-021-01117-y","article-title":"Dasatinib enhances anti-leukemia efficacy of chimeric antigen receptor T cells by inhibiting cell differentiation and exhaustion","volume":"14","author":"Zhang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B173","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1158\/1078-0432.CCR-14-2920","article-title":"CMVpp65 vaccine enhances the antitumor efficacy of adoptively transferred CD19-redirected CMV-specific T cells","volume":"21","author":"Wang","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-021-03215-6","article-title":"Development of CMV-CD19 bi-specific CAR T cells with post-infusion in vivo boost using an anti-CMV vaccine","volume":"114","author":"Wang","year":"2021","journal-title":"Int J Hematol"},{"key":"B175","year":""},{"key":"B176","year":""},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2022.109078","article-title":"Stem cell like memory T cells: A new paradigm in cancer immunotherapy","volume":"241","author":"Wang","year":"2022","journal-title":"Clin Immunol"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1172\/JCI150807","article-title":"CAR T cell manufacturing from naive\/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome","volume":"132","author":"Arcangeli","year":"2022","journal-title":"J Clin Invest"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"key":"B180","doi-asserted-by":"publisher","first-page":"320ra3","DOI":"10.1126\/scitranslmed.aad5222","article-title":"Early memory phenotypes drive T cell proliferation in patients with pediatric Malignancies","volume":"8","author":"Singh","year":"2016","journal-title":"Sci Transl Med"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.03.019","article-title":"Immunophenotype of CAR T cells and apheresis products predicts response in CD22 CAR T cell trial for B cell acute lymphoblastic leukemia","volume":"33","author":"Dreyzin","year":"2025","journal-title":"Mol Ther"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abk1900","article-title":"TSTEM-like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models","volume":"15","author":"Meyran","year":"2023","journal-title":"Sci Transl Med"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-683847","article-title":"Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell Malignancies","volume":"128","author":"Sabatino","year":"2016","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1727926\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T05:37:41Z","timestamp":1776749861000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1727926\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":183,"alternative-id":["10.3389\/fimmu.2026.1727926"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1727926","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"article-number":"1727926"}}